# Predictive Oncology & Therapy

## Impact of Cancer Biotechnology

**Diagnostic & Prognostic Indicators**

### Nice, France • October 26 - 28, 1996


### Biology/Genetics

<table>
<thead>
<tr>
<th>Topic</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNA repair deficiencies</td>
<td>AR SARASIN, PhD</td>
</tr>
<tr>
<td>DNA adduct levels</td>
<td>SA KYRTOPoulos, MD National Hellenic Fdn, Athens</td>
</tr>
<tr>
<td>Telomerase prognosis</td>
<td>JS SHAY, PhD Southwestern Med Ctr, Dallas</td>
</tr>
<tr>
<td>Glycobiology of metastasis</td>
<td>K OLSEN, PhD NIEHS, Res Triangle Park, NC</td>
</tr>
<tr>
<td>Growth factor receptors</td>
<td>P COMOGlio, MD, PhD Univ Turin, Turin, Italy</td>
</tr>
<tr>
<td>Signal transduction</td>
<td>IB WEINSTEIN, MD Columbia Univ Cancer Ctr, NY</td>
</tr>
<tr>
<td>Chronic oxidative stress</td>
<td>LA LOEB, MD, PhD Univ Washington, Seattle</td>
</tr>
<tr>
<td>Genomic instability</td>
<td>CR BOLAND, MD Univ California, San Diego</td>
</tr>
<tr>
<td>Cell transformation by oncogenic retroviruses</td>
<td>L CHIECO BIANCHI, MD Univ Padua, Padua, Italy</td>
</tr>
<tr>
<td>Cell cycle control &amp; differentiation</td>
<td>P HINDS, MD Harvard Med School, Boston</td>
</tr>
<tr>
<td>Oncogene &amp; tumor suppressor gene mutations</td>
<td>M GREENBLATT, MD Univ Vermont Med College, Burlington</td>
</tr>
<tr>
<td>Transgenic mouse models for tumor suppressor genes</td>
<td>HM MATZUK, MD, PhD Baylor College Med, Houston</td>
</tr>
</tbody>
</table>

### Risk Assessment

<table>
<thead>
<tr>
<th>Topic</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple gene mutations</td>
<td>R MONIER, PhD Gustave Roussy, Villejuif</td>
</tr>
<tr>
<td>Molecular genetics</td>
<td>L STRONG, MD UTX MD Anderson Cancer Ctr, Houston</td>
</tr>
<tr>
<td>Carcinogenic susceptibility</td>
<td>S PARODI, MD PhD National Cancer Research Ctr, Genoa</td>
</tr>
<tr>
<td>Precursor lesions</td>
<td>D DMITROVSKY, MD Memorial Sloan-Kettering Ctr, NY</td>
</tr>
<tr>
<td>Biomarkers of carcinogen exposure</td>
<td>R SANTIELLA, PhD Columbia Univ Cancer Ctr, NY</td>
</tr>
<tr>
<td>Management: patients at risk</td>
<td>J HORTON, MD MFFin Cancer Ctr, Tampa</td>
</tr>
</tbody>
</table>

### Novel Therapies

<table>
<thead>
<tr>
<th>Topic</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiogenesis inhibitors</td>
<td>RS KERBEL, PhD Sunnybrook HSC, Toronto</td>
</tr>
<tr>
<td>Molecular screening modalities</td>
<td>J MANDEL, PhD Univ Minnesota, Minneapolis</td>
</tr>
<tr>
<td>Genetically engineered vaccines</td>
<td>C LOCHT, MD Institut Pasteur, Lille</td>
</tr>
<tr>
<td>Reversal of drug resistance</td>
<td>P WIERNIK, MD A Einstein Med Ctr, Bronx, NY</td>
</tr>
<tr>
<td>Antisense therapy</td>
<td>AN GEWIRTZ, MD Univ Pennsylvania, Philadelphia</td>
</tr>
<tr>
<td>Bridging research to clinic</td>
<td>RA GOOD, MD PhD Univ S Florida, St Petersburg</td>
</tr>
<tr>
<td>Molecular genetics lymphoid neoplasms</td>
<td>U JAEGGER, MD Allgemeines Krankenhaus, Vienna</td>
</tr>
<tr>
<td>Choice of gene therapy vectors</td>
<td>R CRISTIANO, MD UTX MD Anderson Cancer Ctr, Houston</td>
</tr>
<tr>
<td>Stem cell delivery systems</td>
<td>P QUESENBERRY, PhD Univ Massachusetts, Worcester</td>
</tr>
<tr>
<td>Retroviral gene therapy</td>
<td>AB DEISSEROTH, MD PhD Yale Cancer Ctr, New Haven</td>
</tr>
<tr>
<td>Adenoviral gene transfer</td>
<td>M PERRICAUDET, PhD Gustave Roussy, Villejuif</td>
</tr>
<tr>
<td>Clinical use of growth factors</td>
<td>J GABRILOVE, MD Memorial Sloan-Kettering Ctr, NY</td>
</tr>
<tr>
<td>Early detection &amp; therapy</td>
<td>V KOROLCHOUK, MD WHO, Geneva</td>
</tr>
</tbody>
</table>

### Predictive Markers

<table>
<thead>
<tr>
<th>Topic</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic markers</td>
<td>K FRENNEL, PhD NYU, NY</td>
</tr>
<tr>
<td>Site-specific markers</td>
<td>WR BRUCE, MD PhD Ontario Cancer Inst, Toronto</td>
</tr>
<tr>
<td>Preneoplastic p53 expression</td>
<td>G SELIVANOVA, MD Karolinska Inst, Stockholm</td>
</tr>
<tr>
<td>Prognostic implications of heat shock proteins</td>
<td>S FUQIA, PhD UTX, San Antonio</td>
</tr>
<tr>
<td>DNA adducts of carcinogen exposure</td>
<td>C WILD, MD IARC, Lyon</td>
</tr>
<tr>
<td>Prognostic oncogene expression</td>
<td>Z RONAI, PhD American Health Fdn, Valhalla, NY</td>
</tr>
</tbody>
</table>

### Deadline for Abstracts • June 28, 1996

Details from: HE Nieburgs MD • Fax: 508-856-1824 • Tel: 212-534-4991 • e-mail: CANCER@BANYAN.ummed.edu

Correspondence: Box 20, University of Massachusetts Medical Center, 55 Lake Ave N, Worcester, MA 01655 USA

Sponsored by the International Society for Preventive Oncology in cooperation with the World Health Organization and The International Agency for Research on Cancer, and cosponsored by the French National League Against Cancer, Curie Institute (Paris), Gustave Roussy Institute (Villejuif), University of Nice Sophia-Antipolis Faculty of Medicine, The Italian National League Against Cancer, National Institute for Research on Cancer (Genoa), Advanced Biotechnology Center (Genoa), University of Illinois College of Medicine (Chicago), University of Massachusetts Medical Center (Worcester), Massachusetts Biotechnology Council.
International Workshop on
NOVEL APPROACHES TO CANCER PREVENTION
ISREC (Swiss Institute for Experimental Cancer Research),
Epalinges sur Lausanne, Switzerland - July 11-13, 1996

Scientific Organizers: B. Hirt (CH) P. Marks (USA) T. Sugimura (J) R. Weil (CH) I.B. Weinstein (USA)
Scientific Secretary: H. Türler (CH)

Program:

Session I: Welcome and Introduction
Overview
Epidemiology of Diet and Cancer
Molecular Epidemiology and Biomarkers

Session II: Hereditary Factors and Molecular Mechanisms
Studies on Familial Cancers
BRCA 1 and Breast Cancer
Genetic Defects in Cancer Cells
Abnormalities in Cell Cycle Control and Their Relevance to Prevention
Biological Significance of Amplification

Session III: Nutritional and Microbial Factors
Colon Cancer
Dietary Factors
H. pylori and Gastric Cancer, Barrett’s Esophagus
Viral Agents

Session IV: Precursor Lesions, Developmental Biology and Differentiation
Mechanistic Studies on Barrett’s Esophagus
Breast Cancer
Differentiation
Errors in stem cell differentiation may lead to carcinoma

Session V: Chemoprevention
Experimental Studies
Clinical Studies
Role of vitamins and carotenoids

Round Table Discussion
Closing Remarks

Free Communications:
A limited number of free communications will be accepted for poster presentation. Abstracts should be sent no later than May 31, 1996 to: Dr. Hans Türler, Département de Biologie Moléculaire, Université de Genève, 30 Quai Ernest Ansermet CH-1211 Genève 4, Switzerland (Fax: +41-22-702 6868).

For further information (program, registration, hotel-reservation and abstract forms), please contact:
M.G. Carli, Secretary of the Board, P.O. Box 7228, 00100 Rome (Nomentano), Italy
Tel. +39-6-70 38 46 94 - Fax +39-6-70 38 45 77
CARCINOGENESIS FROM ENVIRONMENTAL POLLUTION: ASSESSMENT OF HUMAN RISK AND STRATEGIES FOR PREVENTION

Joint Meeting Organized by the American Association for Cancer Research (AACR) and the International Agency for Research on Cancer (IARC)

With the Collaboration of the Hungarian Cancer Society

October 6-9, 1996
Hotel Gellért
Budapest, Hungary

CONFERENCES CHAIRPERSONS
Frederica Perera / New York, USA
Paul Kleihues / Lyon, France

PROGRAM COMMITTEE
Hans-Olov Adami / Uppsala, Sweden
J. Carl Barrett / Research Triangle Park, USA
Paolo Boffetta / Lyon, France
Edward Bresnick / Worcester, USA
Mieczyslaw R. Chorząży / Gliwice, Poland
Joseph F. Fraumeni, Jr. / Bethesda, USA
Waun Ki Hong / Houston, USA
Margaret L. Kripke / Houston, USA
Kenneth Olden / Research Triangle Park, USA
Alán Pintér / Budapest, Hungary
Manfred F. Rajewsky / Essen, Germany
David Zaridze / Moscow, Russia

Keynote Address
Curtis C. Harris / Bethesda, USA

Cancer Incidence and Etiology
Witold A. Zatorzki / Warsaw, Poland
Frederica Perera / New York, USA
J. Carl Barrett / Research Triangle Park, USA
Helmut Bartsch / Heidelberg, Germany

Air, Water, Food, and Soil Contamination
Radim J. Šrám / Prague, Czech Republic
Joellen Lewtas / Research Triangle Park, USA
Wieslaw Jedrychowski / Cracow, Poland
Olav Axelson / Linköping, Sweden

Ambient, Environmental, and Occupation Exposure and Cancer Risk
Mieczyslaw R. Chorząży / Gliwice, Poland
Alán Pintér / Budapest, Hungary
Kimmo Peltonen / Helsinki, Finland
Monica C. Hollstein / Heidelberg, Germany
Kari Hemminki / Stockholm, Sweden

Tobacco
Ivan Plesko / Bratislava, Slovakia
Barbara S. Hulka / Chapel Hill, USA
Paolo L. Vineis / Turin, Italy
Stephen S. Hecht / Valhalla, USA
Krystyna Frenkel / New York, USA
Bernadette Schoket / Budapest, Hungary

Strategies for Prevention
Waun Ki Hong / Houston, USA
I. Bernard Weinstein / New York, USA
Anna Tompa / Budapest, Hungary

Roundtable Discussion
Paul Kleihues / Lyon, France
Hans-Olov Adami / Uppsala, Sweden
Paolo Boffetta / Lyon, France
Edward Bresnick / Worcester, USA
Andrew E. Czeizel / Budapest, Hungary
Terri Damstra / Research Triangle Park, USA
Edith Olah / Budapest, Hungary
Kenneth Olden / Research Triangle Park, USA
Manfred F. Rajewsky / Essen, Germany
William A. Suk / Research Triangle Park, USA
David Zaridze / Moscow, Russia

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
(215) 440-9300  (215) 440-9313 (FAX)
Email: aacr@aol.com
THE UNIVERSITY OF TEXAS
MD ANDERSON CANCER CENTER

The University of Texas
M.D. Anderson Cancer Center
Department of Urology

Multidisciplinary Prostate Cancer Research Program

The University of Texas M. D. Anderson Cancer Center is launching a major new integrated multidisciplinary program in Prostate Cancer Research in conjunction with the Departments of Urology, Cell Biology, and Genitourinary Medical Oncology. Ample resources of dedicated laboratory space and research personnel and a substantial financial base are being secured for this program. We are seeking scientists for faculty positions to add to our critical contingent of researchers interested in the biology and therapy of human prostate cancer.

- A position at the Professor level for a senior scientist with a record of outstanding achievement in research, extramural funding, administration, and graduate training;

- Two positions at the Assistant or Associate Professor level for scientists with exceptional accomplishments in cancer biology (systemic, cellular, molecular, and biochemical).

Candidates should have a Ph.D. or an M.D. degree with a track record of research in molecular biology and interest in the study of prostate cancer. Applicants should send curriculum vitae, a 1–2 page summary of research activities, and the names of three references to:

Andrew C. von Eschenbach, M.D.
Director of the Prostate Cancer Research Program
Chairman, Department of Urology, Box 110
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030

The University of Texas is an Affirmative Action/Equal Opportunity Employer and encourages minorities and women to apply. Smoke-free environment.

POSTDOCTORAL IRTA FELLOW

The Women's Cancers Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health has a postdoctoral research position available to study the molecular and biochemical basis of breast cancer metastasis. A five year appointment funded by an Intramural Research Training Award is available to applicants who are U.S. citizens or permanent residents; hold a doctoral degree in biomedical, behavioral, or related sciences or have been certified as meeting all of the requirements leading to such a doctorate; and have 5 years or less of relevant postdoctoral research experience. Salary commensurate with experience ($25,000–$38,000). Please send c.v. and recent reprints to:

Dr. Patricia Steeg
National Institutes of Health
Building 10, Room 2A33
9000 Rockville Pike
Bethesda, MD 20892

NIH is an Equal Opportunity Employer

MAYO CLINIC
DIVISION OF MEDICAL ONCOLOGY
AND MAYO CANCER CENTER

Clinical Research Positions

The Division of Medical Oncology and the NCI-designated Mayo Cancer Center in Rochester, Minnesota, invite applications for two clinical research positions. Clinical investigators with established cancer research programs are encouraged to apply. The Mayo Clinic provides an outstanding environment for investigators interested in conducting translational research with the goal of improving prevention, diagnosis, and treatment of cancer. Interested applicants should submit a statement of research interests, curriculum vitae, bibliography, and list of references to:

James N. Ingle, M.D.
Associate Director for Clinical Research
Mayo Cancer Center
Mayo Clinic
200 First Street, SW
Rochester, MN 55905

Mayo Foundation is an affirmative action and equal opportunity educator and employer.
Programmed Cell Death

October 19-23, 1996
The Sagamore, Bolton Landing (Lake George), New York

CONFERENCE CHAIRPERSONS

Stanley J. Korsmeyer / St. Louis, MO
Shigekazu Nagata / Osaka, Japan
Andrew H. Wyllie / Edinburgh, Scotland

SCIENTIFIC PROGRAM

Keynote Address
Martin C. Raff / London, England

Development
H. Robert Horvitz / Cambridge, MA
Hermann Steller / Cambridge, MA
Stanley J. Korsmeyer / St. Louis, MO

Oncogenesis
Douglas Hanahan / San Francisco, CA
Mina J. Bissell / Berkeley, CA
Eileen P. White / Piscataway, NJ
Gerard I. Evan / London, England

Death Antagonists
Suzanne Cory / Melbourne, Australia
Craig B. Thompson / Chicago, IL
Lois K. Miller / Athens, GA

Death Signals
Shigekazu Nagata / Osaka, Japan
Peter Krammer / Heidelberg, Germany
David V. Goeddel / S. San Francisco, CA
George D. Yancopoulos / Tarrytown, NY

Death Effectors
Junying Yuan / Charlestown, MA
Donald W. Nicholson / Pointe-Claire-Dorval, Quebec, Canada
Vishva Dixit / Ann Arbor, MI
Arnold H. Greenberg / Winnipeg, Manitoba, Canada

Survival Signals
Andrew H. Wyllie / Edinburgh, Scotland
Tadatsugu Taniguchi / Tokyo, Japan
Ken-ichi Arai / Tokyo, Japan

Resistance and Therapeutics
Michael B. Kastan / Baltimore, MD
Richard N. Kolesnick / New York, NY

Additional Speakers to be Announced

Applicants are encouraged to submit abstracts for poster presentation.

Application deadline: August 2, 1996

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300  215-440-9313 (FAX)
E-mail: aacr@aol.com
Texas Tech University Health Sciences Center

A Post-Doctoral Position is available immediately to study drug resistance and cancer. Candidate should have a Ph.D. or M.D. degree with background in drug resistance and molecular biology. Good salary, excellent working environment. Send curriculum vitae to:

Maria Claudia Mallarino, M.D.
Texas Tech University Health Sciences Center
Oncology Division
Department of Internal Medicine
3601 4th Street
Lubbock, Texas 79430

Phone: (806) 743-3155; Fax: (806) 743-3148

MOLECULAR/GENETIC EPIDEMIOLOGIST

The Section of Clinical Epidemiology at Mayo Clinic, in collaboration with the Mayo Cancer Center, is seeking a molecular/genetic epidemiologist to fill a new position in our large and active group. This position presents an exciting opportunity for the successful candidate to conduct population-based molecular epidemiologic studies of the occurrence, etiology, and outcomes of cancers, as well as evaluations of the impact of diagnostic and therapeutic interventions in these conditions.

Applicants should have a strong methodologic training in epidemiology with evidence of research productivity in molecular epidemiology as reflected by peer-reviewed publications and a demonstrated ability to attract extramural research funding. This individual will be expected to develop an independent program of research in collaboration with clinical and laboratory investigators.

The Mayo Clinic, with a research budget in excess of $130 million per year, provides an outstanding environment for conducting molecular epidemiologic research. Resources include: The Rochester Epidemiology Project, with its linkage of medical records for residents of Olmsted County back to the early 1900s, a large referral practice as reflected by over 150,000 cases recorded in the Mayo Tumor Registry, tissue archives from the local and referral practice, and an exceptional collaborative atmosphere among clinicians, basic scientists, epidemiologists, and biostatisticians.

Academic rank for the successful applicant will depend on qualifications and experience. There are no clinical practice responsibilities associated with this position. Salary and benefits are most competitive.

Rochester, Minnesota provides a remarkable quality of life, as evidenced by its #1 (1993) and #2 (1994, 1995) ranking in Money Magazine.

Qualified applicants should submit a current curriculum vitae to:

Steven J. Jacobsen, M.D., Ph.D.
Head, Section of Clinical Epidemiology
Mayo Clinic, 200 First Street, SW
Rochester, MN 55905
(507)284-5544

Mayo Foundation is an affirmative action and equal opportunity educator and employer.
John Mendelsohn has conducted basic and therapeutic research on cancer for the past 25 years and has directed academic medical oncology programs over the past 18 years. In 1977, he was appointed the founding Director of a new NCI-designated cancer center at the University of California, San Diego. Since 1985, he has led the medical oncology program at Memorial Sloan-Kettering Cancer Center as Chairman of the Department of Medicine. In addition, for a period of 5 years, he was Co-Head of the Program in Molecular Pharmacology and Therapeutics of the Sloan-Kettering Institute. In fostering strong interdisciplinary collaborations between laboratory scientists and clinical investigators, Dr. Mendelsohn has focused on the translation of research discoveries into clinical trials.

In his own research laboratory, Dr. Mendelsohn explores the regulation of signal transduction pathways in normal and malignant cells. Soon after the discovery that the growth factors that activate tyrosine kinases regulate cell proliferation, Dr. Mendelsohn proposed that receptor blockade with monoclonal antibodies (MAbs) might be a novel form of anticancer therapy. He and his collaborators produced MAbs that block binding of epidermal growth factor (EGF) to its receptor and inhibit ligand-induced activation of receptor tyrosine kinase. Further studies demonstrated inhibition of tumor cell proliferation in culture and in xenografts. Evidence for overexpression of EGF receptors in many types of human tumors accumulated during this period, and Dr. Mendelsohn's MAbs were used in his laboratory and by many others to demonstrate autocrine growth regulation by this receptor in malignant breast, colon, prostate, lung, renal, and ovarian cell lines. MAb action required bivalency for optimal antiproliferative activity. Further studies showed that when cells produce both the receptor and the ligand, activation of EGF receptors occurs primarily on the cell surface, rather than by an intracellular mechanism. This body of work has provided strong support for the validity of the autocrine hypothesis of tumor cell stimulation by growth factors.

In 1991, Dr. Mendelsohn and his collaborators reported the results of a Phase I clinical trial in patients with lung cancer, demonstrating the capacity of anti-EGF receptor MAbs to localize in these EGF receptor-bearing tumors and establishing the safety of exposing patients to saturating levels of a receptor-blocking agent for a period of days. Clinical trials with a human-chimeric MAB were initiated in 1994. A recent discovery is the synergistic, curative antitumor activity against human tumor xenografts when chemotherapy (Cisplatin, Doxorubicin, or Taxol) is combined with blockade of EGF receptor-mediated signal transduction. The mechanism may involve activation of apoptosis by simultaneously challenging two checkpoints in cell cycle regulation. These findings have recently been translated into clinical trials of combined anti-EGF receptor MAB and chemotherapy. Dr. Mendelsohn's research has been continuously funded for 25 years by peer-reviewed grants, including a current MERIT award.

Dr. Mendelsohn recently rotated off the Board of Scientific Counselors of the NCI Division of Cancer Treatment, where he was a strong proponent of biological therapies. For 3 years, he chaired the Clinical Trials Program Projects Study Section; during his tenure, review criteria were strengthened and research activities funded by this mechanism became more focused and integrated with basic science. While in California, he served on the Board of Directors of the San Diego Branch of the American Cancer Society, was awarded an American Cancer Society Professorship in Clinical Oncology, and was a member of the Governor's Cancer Council.

A member of the American Association for Cancer Research (AACR) since 1977, Dr. Mendelsohn has been a vital participant in Association activities. He was elected to the Board of Directors for a 3-year term beginning in 1990, and he served as Chairperson of the Publications Committee from 1991–94 and of the Nominating Committee from 1987–89. Other committees on which he has participated include: Finance (1991–94); Scientific and Public Affairs (1985–87); and Membership (1981). He was an Associate Editor for Cancer Research from 1986–95, and he is the founding Editor-in-Chief of Clinical Cancer Research, a new clinical and translational research journal published by the AACR.

Commencing publication in January 1995, Clinical Cancer Research received a remarkable 500 submissions in its first year, and 200 articles were published within the 1,661 pages of its inaugural volume. Current 1996 submission data are keeping pace with those of the previous year, indicating that the journal has already established itself as an optimal publication outlet in its field. The journal's mission is to publish original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical and translational research which bridges the laboratory and the clinic, aiming to report new studies that can transform basic research findings into actual clinical interventions in the management of cancer patients and those individuals who are at high risk for developing cancer. Further testimony to the excitement Clinical Cancer Research has generated can be seen in the 4,233 subscribers (including about 2,300 institutions) it has garnered since its inception only about 16 months ago. Dr. Mendelsohn's visionary leadership has been an integral factor in the rapid success of the journal. We are grateful to him for his steadfast and energetic stewardship during the critical formation stages of the journal and look forward to his continued guidance as the journal strives to fulfill its mission.

In addition to his work on AACR publications, Dr. Mendelsohn has authored many chapters and review articles on growth factors and their role in cancer in other leading journals and textbooks, and he is Editor-in-Chief of a new textbook entitled The Molecular Basis of Cancer.

Dr. Mendelsohn received his M.D. from Harvard Medical School, Boston, MA, in 1963. He served his internship and was Assistant Resident in Medicine at Peter Bent Brigham Hospital in Boston. After a stint as Research Associate at the NIH in Bethesda, MD, he returned to Peter Bent Brigham Hospital as a Senior Resident and was an Assistant in Medicine at Harvard Medical School. He then served a Fellowship in Hematology and was an Instructor of Medicine at Washington University, St. Louis, MO, before moving on to the University of California, San Diego.

His wife Anne produces documentaries and educational programs for public television. They have three sons, one of whom has chosen a career in the History of Science and Medicine.

Sidney Weinhouse